Contineum Therapeutics (CTNM) financial statements
Net income was -$60M.
Free cash flow was -$56M.
The diluted share count rose 716% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Contineum Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $50M | $0 | — |
| Research and development | $28M | $38M | $52M |
| Selling, general and admin | $6M | $12M | $17M |
| Operating income | $16M | -$51M | -$68M |
| Interest expense | $208,000 | $0 | — |
| Pre-tax income | $23M | -$42M | -$60M |
| Income tax | $450,000 | $0 | $0 |
| Net income | $23M | -$42M | -$60M |
| EPS (diluted) | $0.08 | -$2.18 | -$2.17 |
| Diluted shares | 3M | 19M | 28M |
| Operating margin | 32.2% | — | — |
| Net margin | 45.4% | — | — |
Balance sheet
Fiscal years, from Contineum Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $125M | $205M | $263M |
| Total current assets | $128M | $206M | $268M |
| Property, plant and equipment | $678,000 | $989,000 | $830,000 |
| Total assets | $130M | $213M | $277M |
| Total current liabilities | $5M | $10M | $10M |
| Total liabilities | $6M | $15M | $16M |
| Shareholders' equity | -$68M | $198M | $261M |
| Net debt | -$16M | -$22M | -$76M |
Cash flow
Fiscal years, from Contineum Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | $19M | -$33M | -$55M |
| Capital spending | $414,000 | $514,000 | $231,000 |
| Free cash flow | $19M | -$33M | -$56M |
| Stock-based compensation | $2M | $7M | $10M |
| Net borrowing | -$4M | $0 | — |
| Free cash flow margin | 37.9% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CTNM.
Open CTNM in InvestinglyQuestions
How much free cash flow does Contineum Therapeutics generate?
-$56M in fiscal 2025 (operating cash flow minus capital spending).
From Contineum Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.